Canadian Pacific Kansas City Limited Common Shares vs Novavax Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.98B), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 40.6× Novavax Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| CP | NVAX | |
|---|---|---|
Market Cap | $73.98B | $1.82B |
Volume | 1,669,828 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $96.69 | $12.56 |
52-Week Low | $68.88 | $6.22 |
Enterprise Value | $91.36B | $1.39B |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 59 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →